NovoCure Limited is a commercial-stage oncology company pioneering a novel, proprietary therapy called Tumor Treating Fields (TTFields). TTFields therapy is delivered via wearable, non-invasive medical devices—such as Optune, Optune Lua, and Optune Gio—that generate electric fields to disrupt the division of cancer cells, inhibiting tumor growth and causing cell death. The company's primary revenue source is the prescription and ongoing use of its TTFields delivery systems by patients. NovoCure's products are approved in multiple regions, including the United States, Europe, and Japan, for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma, and non-small cell lung cancer. The company is also conducting numerous clinical trials to expand the application of TTFields to other solid tumor types, such as pancreatic cancer, ovarian cancer, and brain metastases. Geographically, the majority of NovoCure's revenues are generated in the United States, Germany, and Japan. The company operates with a direct sales force and provides extensive patient support services to ensure compliance and proper use of its devices.
